Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Inte
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.
Authors
- Nigel Lever (ORCID: https://orcid.org/0000-0002-4812-9001)
- Karol Čurila (ORCID: https://orcid.org/0000-0003-3523-6358)
- Jamie Manlucu
- Haran Burri
- Maria-Grazia Bongiorni
- Robert Schaller
- Óscar Cano
- Sergio Richter
- Julien Dreyfus
- Christophe Leclercq
- Antonio Mangieri
- Hung-Fat Tse
- Christoph Thomas Starck
- Blandine Mondésert
- Zachary Whinnett
- Jens Cosedis Nielsen
- Fabien Praz
- Nicolas Amabile
- Archana Rao
- Jean-claude Deharo
- Christian Veltmann
- Michael Glikson
- Maully Shah
- Pascal Defaye
- Alexander Breitenstein
Publication Details
- Journal
- Universität Zürich, ZORA
- Published
- 2025-05-01
- DOI
- https://doi.org/10.5167/uzh-291738
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00